BRAF V600E Expression Is a Novel Prognostic Marker in Primary Melanoma

Share this content:
The presence of a BRAF V600E mutation has been used to guide treatment in patients with primary melanoma, but expression may predict prognosis.
The presence of a BRAF V600E mutation has been used to guide treatment in patients with primary melanoma, but expression may predict prognosis.

The presence of a BRAF V600E mutation has been used to guide treatment in patients with primary melanoma, but according to a study published in the British Journal of Cancer, BRAF V600E expression may predict prognosis in those patients as well.1

Although about half of all primary melanomas harbor BRAF mutations, the prognostic impact of those mutations has been unclear. Because a BRAF V600E mutation-specific antibody has recently become available for immunohistochemistry, researchers sought to investigate the prognostic impact of BRAF V600E protein expression in patients with primary melanoma.

 

For the study, researchers assessed BRAF V600E and total BRAF expression by immunohistochemistry using tissue microarray sections of paraffin-embedded archival tissue from 248 nodular melanomas. Of those cases, 191 had sufficient tumor tissue to evaluate mutation status by real-time polymerase chain reaction.

Investigators observed positive BRAF V600E expression in 35% of the 248 nodular melanomas. Results showed that expression was significantly associated with increased tumor thickness, presence of tumor ulceration, and worse survival.

RELATED: Statin Use May Increase Risk of Non-melanoma Skin Cancer Risk in Postmenopausal Women

In multivariate analysis, researchers found that BRAF V600E expression was an independent prognostic factor while BRAF mutation status was not significant.

“Our findings indicate that BRAF V600E expression is a novel prognostic marker in primary melanoma,” the authors concluded.

Reference

  1. Hugdahl E, Kalvenes MB, Puntervoll HE, et al. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival [published online ahead of print February 25, 2016]. Br J Cancer. doi: 10.1038/bjc.2016.44.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs